ProBio Licenses Antibody Asset to AbTis for ADC Work
AbTis gains exclusive global rights to a discovery-stage oncology antibody to develop into a next-generation antibody-drug conjugate.
Updated on Nov. 11, 2026 in Biotech

ProBio, a global contract research, development, and manufacturing organization, has entered an exclusive global licensing agreement with South Korean biotechnology company AbTis Co., Ltd. under which AbTis will develop a discovery-stage antibody asset generated by ProBio into a next-generation antibody-drug conjugate (ADC).
Why it matters
The deal pairs ProBio's biologics discovery capabilities with AbTis's site-specific conjugation technology, a combination intended to accelerate development of an oncology asset. It reflects continued interest in ADCs as a therapeutic class.
The antibody asset was generated through ProBio's biologics discovery work against an oncology target, and AbTis will apply its AbClick® site-specific conjugation platform to advance it. Financial terms, including the upfront payment amount, were not disclosed.
The players
ProBio
ProBio is a global contract research, development, and manufacturing organization (CRDMO) that offers biologics discovery and development services.
AbTis Co., Ltd.
AbTis is a South Korean biotechnology company and subsidiary of Dong-A ST that specializes in site-specific conjugation technologies for antibody-drug conjugates.
The details
Under the exclusive global agreement, AbTis receives rights to develop and commercialize the discovery-stage antibody, with ProBio receiving an upfront payment plus potential developmental and commercial milestones and royalties. AbTis CEO Dr. Hyungsuk Choi and ProBio CEO Allen Guo are the leaders of the respective companies.
Timeline
November 11, 2026: ProBio announced the licensing agreement with AbTis.
The Tech Race
The agreement fits a broader push among drug developers to combine discovery-stage antibodies with site-specific conjugation platforms, a method aimed at producing more uniform next-generation ADCs. AbTis is also expanding its pipeline into bispecific antibody-drug conjugates.
For patients, this deal is a discovery-stage development with no near-term treatment change. Any resulting therapy would require clinical trials before it could reach patients.
The takeaway
Licensing deals like this one show how drug developers are splitting work across specialized partners, with discovery firms supplying antibodies and conjugation specialists building the final drug. Readers following oncology should watch for clinical progress rather than licensing terms alone.
Further reading
Explore more Biotech coverage for context on antibody-drug conjugate development.



